How to use anti-leukotrienes in the treatment of asthma

  • J. C. Kips
  • R. A. Pauwels
Chapter

Abstract

Asthma is currently defined as a chronic inflammatory disease of the airways. The goals of proper asthma therapy, as put forward in recent guidelines, are not only to prevent symptoms and exacerbations, but also to allow for normal activity levels and maintain pulmonary function within near normal limits1. In order to achieve these goals, a stepwise therapeutic approach has been adopted. This is based on obvious avoidance measures, in combination with pharmacological intervention. Medication used for asthma treatment is broadly categorized into two classes: long-term medication, used to achieve and maintain control of the disease, and immediate relief medication, used to treat acute symptoms and exacerbations.

Keywords

Allergy Clin Immunol Asthmatic Subject Moderate Asthma Nocturnal Asthma Resp Crit 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    GINA report. International Consensus report on diagnosis and management of asthma. US Dept Health and Human Services, 1992.Google Scholar
  2. 2.
    Lam S, Chan H, Leriche JC, Chan-Yeung M, Salad H. Release of leukotrienes in patients with bronchial asthma. J Allergy Clin Immunol. 1988; 81: 711–17.PubMedCrossRefGoogle Scholar
  3. 3.
    Adelroth E, Morris MM, Hargreave FE, O’Byrne P. Airway responsiveness to leukotrienes C4 and D4 and to methacholine in patients with asthma and normal controls. N Engl J Med. 1986; 315: 480–4.PubMedCrossRefGoogle Scholar
  4. 4.
    Drazen JM, Austen KF. Leukotrienes and airway responses. Am Rev Resp Dis. 1987; 136: 985–98.PubMedCrossRefGoogle Scholar
  5. 5.
    Laitinen LA, Laitinen A, Haahtela T, Vilkka V, Spur BW, Lee TH. Leukotriene E4and granulocytic infiltration into asthmatic airways. Lancet. 1993; 341: 989–90.PubMedCrossRefGoogle Scholar
  6. 6.
    Hay DWP, Torphy TJ, Undem BJ. Cysteinyl leukotrienes in asthma: Old mediators up to new tricks. TiPS. 1995; 16: 304–09.PubMedGoogle Scholar
  7. 7.
    Cohen P, Noveral JP, Bhala A, Nunn SE, Herrick DJ, Grunstein MM. Leukotriene D4facilitates airway smooth muscle cell proliferation via modulation of the IGF axis. Am J Physiol. 1995; 269: L151–7.PubMedGoogle Scholar
  8. 8.
    Gaddy JN, Margolskee DJ, Bush RK, Williams VC, Busse WW. Bronchodilation with a potent and selective leukotriene D4 (LTD4) receptor antagonist (MK-571) in patients with asthma. Am Rev Resp Dis. 1992; 146: 358–63.PubMedCrossRefGoogle Scholar
  9. 9.
    Hui KP, Barnes NC. Lung function improvement in asthma with a cysteinyl-leukotriene receptor antagonist. Lancet. 1991; 337: 1062–3.PubMedCrossRefGoogle Scholar
  10. 10.
    Reiss TF, Sorkness CA, Stricker W, et al. Effects of montelukast (MK-0476), a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled corticosteroids. Thorax. 1997; 52: 45–8.PubMedCrossRefGoogle Scholar
  11. 11.
    Israel E, Juniper EF, Callaghan JT, et al. Effect of a leukotriene antagonist, LY 171883 on cold air-induced bronchoconstriction in asthmatics. Am Rev Resp Dis. 1989; 140: 1348–53.PubMedCrossRefGoogle Scholar
  12. 12.
    Manning PJ, Watson RM, Margolskee DJ, Williams VC, Schwartz JI, O’Byrne PM. Inhibition of exercise-induced bronchoconstriction by MK-571, a potent leukotriene D4-receptor antagonist. N Engl J Med 1990; 323: 1736–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Finnerty JP, Wood-Baker R, Thomson H, Holgate ST. Role of leukotrienes in exercise-induced asthma. Am Rev Resp Dis. 1992; 145: 746–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Taylor IK, O’Shaughnessy KM, Fuller RW, Dollery CT. Effect of cysteinyl-leukotriene receptor antagonist ICI 204,219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects. Lancet. 1991; 337: 690–4.PubMedCrossRefGoogle Scholar
  15. 15.
    Rasmussen JB, Eriksson L-O, Margolskee DJ, Tagari P, Williams VC, Andersson K-E. Leukotriene D4receptor blocker inhibits the immediate and late bronchoconstrictor responses to inhaled antigen in patients with asthma. J Allergy Clin Immunol. 1992; 90: 193–201.PubMedCrossRefGoogle Scholar
  16. 16.
    Kane GC, Pollice M, Kim C-J, et al. A controlled trial of the effect of the 5-lipoxygenase inhibitor, zileuton, on lung inflammation produced by segmental antigen challenge in human beings. J Allergy Clin Immunol. 1996; 97: 646–54.PubMedCrossRefGoogle Scholar
  17. 17.
    Wenzel SE, Trudeau JB, Kaminsky DA, Cohn J, Martin RJ, Westcott JY. Effect of 5-lipoxygenase inhibition on bronchoconstriction and airway inflammation in nocturnal asthma. Am J Resp Crit Care Med. 1995; 152: 897–905.PubMedCrossRefGoogle Scholar
  18. 18.
    Calhoun WJ, Williams KL, Simonson SG, Lavins BJ. Effect of zafirlukast (AccolateTM) on airway inflammation after segmental allergen challenge in patients with mild asthma. Am J Respir Crit Care Med. 1997; 155: A662.Google Scholar
  19. 19.
    Leff JA, Pizzichini E, Efthimiadis A, et al. Effect of montelukast (MK-0476) on airway eosinophilic inflammation in mildly uncontrolled asthma: A randomized placebo-controlled trial. Am J Resp Crit Care Med. 1997; 155: A977.Google Scholar
  20. 20.
    Liu MC, Dube LM, Lancaster J, Zileuton Study Group. Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: A 6-month randomized multicenter trial. J Allergy Clin Immunol. 1996; 98: 859–71.CrossRefGoogle Scholar
  21. 21.
    Calhoun WJ, Weisberg SC, Faiferman I, Stober PW. Pranlukast (UltairTM) is effective in improving asthma: results of a I2-week, multicenter, dose-ranging study. J Allergy Clin Immunol. 1997; 99. S318.Google Scholar
  22. 22.
    Spector SL, Smith LJ, Glass M. Effect of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. Am J Resp Crit Care Med. 1994; 150: 618–23.PubMedCrossRefGoogle Scholar
  23. 23.
    Tashkin DP, Nelson HS, Cohn J, Hanby LA, Miller CJ. Efficacy and safety of zafirlukast (Accolate) in patients with mild to moderate asthma. Am J Resp Crit Care Med. 1996; 153: A534.CrossRefGoogle Scholar
  24. 24.
    Suissa S, Dennis R, Ernst P, Sheehy O, Wooddauphine. Effectiveness of the leukotriene receptor antagonist zafirlukast for mild-to-moderate asthma - a randomized double-blind, placebo-controlled trial. Ann Intern Med. 1997; 126: 177.PubMedCrossRefGoogle Scholar
  25. 25.
    Reiss TF, Chervinsky P, Edwards T, et al. Montelukast Study Group. Montelukast (MK-0476), a Cys LT1 receptor antagonist, improves asthma outcomes over a 3-month treatment period. Am J Resp Crit Care Med. 1997; 155: A662.Google Scholar
  26. 26.
    Sahn S, Galant S, Murray J, et al., on behalf of the Ultair Study Group. Pranlukast (UltairTM) improves FEV1, in patients with asthma: results of a 12-week multicenter study vs Nedocromil. Am J Resp Crit Care Med..1997; 155: A665.Google Scholar
  27. 27.
    Nathan RA, Glass M, Snader L. Effects of 13 weeks of treatment with ICI 204,219 (AccolateTM) or cromolyn sodium (IntalTM) in patients with mild to moderate asthma. J Allergy Clin Immunol. 1995; 95: S388.Google Scholar
  28. 28.
    Wenzel P, Chervinsky P, Kerwin E, Silvers W, Faiferman I, Dubb J. Oral pranlukast (UltairTM) vs inhaled beclomethasone: Results of a 12-week trial in patients with asthma. Am J Resp Crit Care Med. 1997; 155: A203.Google Scholar
  29. 29.
    Tamaoki J, Kondo M, Sakai N, et al. Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid. Am J Resp Crit Care Med. 1997; 155: 1235–40.PubMedCrossRefGoogle Scholar
  30. 30.
    Bateman ED, Holgate ST, Binks SM, Tams IP. A multicenter study to assess the steroid-sparing potential of AccolateTM (Zafirlukast; 20mg BD). Allergy. 1995; 50: P-0709.Google Scholar
  31. 31.
    Laitinin LA, Zetterstrom O, Holgate ST, Binks SM, Whitney JG. Effects of AccolateTM (Zafirlukast; 20mg BD) in permitting reduced therapy with inhaled steroids: a multicenter trial in patients with doses of inhaled steroid optimised between 800 and 2000 mcg per day. Allergy. 1995; 50: P-0710.Google Scholar
  32. 32.
    O’Connor BJ, Godard P, Dube LM, Swanson LI, Rountree LV. The effect of 5-lipoxygenase inhibitor, zileuton, plus low-dose inhaled beclomethasone compared to higher dose beclomethasone alone in patients with asthma. Am J Resp Crit Care Med. 1996; 153: A803.Google Scholar
  33. 33.
    Christie PE, Tagari P, Ford-Hutchinson AW, et al. Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin sensitive asthmatic subjects. Am Rev Resp Dis. 1991; 143: 1025–9.PubMedCrossRefGoogle Scholar
  34. 34.
    Arm JS, O’Hickey S, Spur BW Lee TH. Airway responsiveness to histamine and leukotriene E4 in subjects with aspirin-induced asthma. Am Rev Resp Dis. 1987; 140: 148–53.Google Scholar
  35. 35.
    Dahlén B, Margolskee DJ, Zetterstrom O, Dahlén S-E. Effect of the leukotriene receptor antagonist MK-0679 on baseline pulmonary function in aspirin sensitive asthmatic subjects. Thorax. 1993; 48: 1205–10.PubMedCrossRefGoogle Scholar
  36. 36.
    Israel E, Fischer AR, Rosenberg MA, et al. The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. Am Rev Resp Dis. 1993; 148: 1447–51.PubMedCrossRefGoogle Scholar
  37. 37.
    Kuna P, Malmstrom K, Dahlén S-E, et al. Montelukast (MK-0476), a CysLT1 antagonist, improves asthma control in aspirin-intolerant asthmatic patients. Am J Resp Crit Care Med. 1997; 155: A975CrossRefGoogle Scholar
  38. 38.
    The British Guidelines on asthma management 1995. Review and position statement. Thorax. 1997; 52: SI-21.Google Scholar
  39. 39.
    Guidelines for the diagnosis and management of asthma. Bethesda, MD: National Institutes of Health. February 1997.Google Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1998

Authors and Affiliations

  • J. C. Kips
  • R. A. Pauwels

There are no affiliations available

Personalised recommendations